The consortium has bridged the treatment gap for young children by developing a child-friendly tablet formulation of praziquantel. Photo: Danielle Powell, Swiss TPH
The consortium has bridged the treatment gap for young children by developing a child-friendly tablet formulation of praziquantel. Photo: Danielle Powell, Swiss TPH - The Pediatric Praziquantel Consortium receives funding for the implementation of the ADOPT programme, which paves the way for the introduction of a child-friendly formulation to treat schistosomiasis in preschool-aged children. Swiss TPH, as a consortium partner, is co-leading the ADOPT programme. The Pediatric Praziquantel Consortium is an international public-private partnership dedicated to the development of a pediatric formulation to treat schistosomiasis in preschool-aged children. The consortium has received renewed funding from the Global Health Innovative Technology (GHIT) Fund and the European and Developing Countries Clinical Trials Partnership (EDCTP). Preparing large-scale access and delivery of the novel formulation The funding will support the ADOPT programme, which is an implementation research programme that supports with the large-scale access and delivery of the consortium's novel pediatric medication in endemic countries. The clinical development programme has progressed to Phase III, with a pivotal trial being run in Kenya and Côte d'Ivoire to generate confirmatory data for registration of the novel pediatric formulation.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
